

# Magellan Rx Formulary

## Standard and Precision Formulary Updates

The Magellan Rx Management Pharmacy & Therapeutics Committee (P&T) and Value Assessment Committee (VAC) meet periodically to review the status of drugs on the formulary and determine updates that are needed due to newly approved products, changes in practice guidelines, updates in FDA approved labeling and/or changes in financial implications. The following is the list of determinations made through this review process for the Magellan Rx Standard and Precision commercial formularies.

REVIEW DATE	LABEL NAME	INDICATIONS	CHANGE TYPE	PRECISION	PRECISION UM	EFFECTIVE DATE
<b>NEW DRUGS</b>						
Mar-22	BUFFERED LIDOCAINE 0.9% SYRNGE		NEW NDC	NF	(NFDA) (MED)	Mar-22
Mar-22	CARDIOPLEGIA 100 MEQ K/500 ML		NEW NDC	NF	(NFDA) (MED)	Mar-22
Mar-22	METHYLPREDNISOLONE AC 80 MG/ML	Glucocorticoid with multiple indications	NEW GENERIC	NF	(NFDA) (MED)	Mar-22
Mar-22	TRIAMCINOLONE ACET 40 MG/ML	Corticosteroid for IM or IA injection	NEW GENERIC	NF	(NFDA) (MED)	Mar-22
Mar-22	AMLADEX TABLET		NEW BRAND	NF	(NFDA)	Mar-22
Mar-22	PRIMIDAR 31B CFU CAPSULE		NEW BRAND	NF	(NFDA)	Mar-22
Mar-22	PROXIVOL 2% GEL	Topical wound gel for pressure ulcers, Venous stasis ulcers, First and second degree burns, and Superficial wounds and scrapes	NEW GENERIC	NF	(NFDA)	Mar-22
Mar-22	SZOSIL 2" X 5.5" GEL SHEET	Silicone adhesive for topical treatment of wounds	NEW FORMULATION	NF	(NFDA)	Mar-22
Mar-22	WESCAPS CAPSULE	vitamin deficiency,vitamin deficiency prevention	NEW GENERIC	NF	(NFDA)	Mar-22
Mar-22	ASCLERA 10 MG/2 ML (0.5%) AMP	varicose veins	NEW NDC	NF	(MED)	Mar-22
Mar-22	ASCLERA 20 MG/2 ML (1%) AMPULE	varicose veins	NEW NDC	NF	(MED)	Mar-22
Mar-22	CASIRIVIMAB-IMDEVIMAB 2VL(EUA)	Treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adult and pediatric patients (see PI for full indication)	NEW GENERIC	NF	(MED)	Mar-22
Mar-22	ILLUCCIX CONFIGURATION A KIT	Indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer	NEW BRAND	NF	(MED)	Mar-22
Mar-22	ILLUCCIX CONFIGURATION B KIT	Indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer	NEW BRAND	NF	(MED)	Mar-22
Mar-22	MIDASPOT COVID19 ANTIBODY TEST	COVID-19 antibody screening test	NEW GENERIC	NF	(MED)	Mar-22
Mar-22	SELENIOS ACID 12 MCG/2 ML VL	selenium deficiency	NEW GENERIC	NF	(MED)	Mar-22
Mar-22	VASOPRESSIN 20 UNIT/ML VIAL	hypotension due to distributive shock	NEW GENERIC	NF	(MED)	Mar-22
Mar-22	COLLANEX POWDER VIAL	Applied to wounds to aid in healing	NEW BRAND	NF		Mar-22

REVIEW DATE	LABEL NAME	INDICATIONS	CHANGE TYPE	PRECISION	PRECISION UM	EFFECTIVE DATE
Mar-22	ZILOVAL 5% OINTMENT-DRESSNG KT	administration of local anesthesia,local anesthesia for endotracheal intubation,minor skin wound pain,pruritus of skin,skin irritation	NEW GENERIC	NF		Mar-22
Mar-22	BACTERIOSTATIC WATER-TRAZIMERA	Drug diluent for Trazimera reconstitution	NEW GENERIC	GEN	(MED) (SP)	Mar-22
Mar-22	LANREOTIDE 120 MG/0.5 ML SYRNG	acromegaly,carcinoid syndrome,malignant gastroenteropancreatic neuroendocrine tumor	NEW BRAND	NPS	(PA) (SP) (BSP) (QPD)	Mar-22
Mar-22	BETAINE 1 GRAM/1.9 ML POWDER	homocystinuria	NEW GENERIC	GEN	(PS) (SP)	Mar-22
Mar-22	MARAVIROC 150 MG TABLET	CCR5 tropic HIV infection	NEW GENERIC	GEN	(PS) (SP)	Mar-22
Mar-22	MARAVIROC 300 MG TABLET	CCR5 tropic HIV infection	NEW GENERIC	GEN	(PS) (SP)	Mar-22
Mar-22	GLYCOPYRROLATE 1 MG/5 ML SOLN	sialorrhoea	NEW GENERIC	GEN		Mar-22
Mar-22	TIBSOVO 250 MG TABLET	acute myeloid leukemia with IDH1 mutation,choleangiocarcinoma with IDH1 mutation	NEW NDC	NPS	(PA) (SP)	Mar-22
Mar-22	APRETUDE ER 600 MG/3 ML VIAL	HIV infection,HIV infection pre-exposure prophylaxis	NEW BRAND	NF	(SP) (MED) (QL)	Jul-22
Mar-22	ENJAYMO 1,100 MG/22 ML VIAL	reduce blood transfusions in cold agglutinin disease	NEW BRAND	NF	(QL) (SP) (MED)	Jul-22
Mar-22	KIMMTRAK 100 MCG/0.5 ML VIAL	uveal melanoma in HLA-A *02:01 positive patient	NEW BRAND	NF	(QL) (SP) (MED)	Jul-22
Mar-22	PEMFEXY 500 MG/20 ML VIAL	malignant mesothelioma of pleura,nonsquamous non-small cell lung cancer	NEW BRAND	NF	(QL) (SP) (MED)	Jul-22
Mar-22	ALIMTA 100 MG VIAL	malignant mesothelioma of pleura,nonsquamous non-small cell lung cancer	DRUG CHANGES	NPS-->NF	(MED)(SP)	Jul-22
Mar-22	ALIMTA 500 MG VIAL	malignant mesothelioma of pleura,nonsquamous non-small cell lung cancer	DRUG CHANGES	NPS-->NF	(MED)(SP)	Jul-22
Mar-22	LEQVIO 284 MG/1.5 ML SYRINGE	adjunct to diet and maximally tolerated statin therapy for the treatment of adults with HeFH or ASCVD, who require additional lowering of low-density lipoprotein cholesterol (LDL-C)	NEW BRAND	NF	(QL) (SP) (MED)	Jul-22
Mar-22	TEZSPIRE 210 MG/1.91 ML SYRING	refractory extrinsic asthma	NEW BRAND	NF	(SP) (MED) (QL)	Jul-22
Mar-22	LEVOFLOXACIN 1.5% EYE DROPS	bacterial conjunctivitis	NEW GENERIC	GEN	QL	Jul-22
Mar-22	PREHEVBRIO 10 MCG/ML VIAL	hepatitis B vaccination	NEW BRAND	PB		Jul-22
Mar-22	XARELTO 1 MG/ML SUSPENSION	treatment of VTE and reduction in the risk of recurrent VTE; thromboprophylaxis with congenital heart disease after the Fontan procedure in pediatric patients (see PI for full indication)	NEW FORMULATION	PB	(QL)	Jul-22
Mar-22	EULEXIN 125 MG CAPSULE	prostatic carcinoma	NEW BRAND	NPB	(ST: T/F generic flutamide caps)	Jul-22
Mar-22	DARTISLA ODT 1.7 MG TABLET	adjunct therapy for peptic ulcer disease	NEW BRAND	NPB	QL (4 tab/day)	Jul-22
Mar-22	FLEQSUVY 25 MG/5 ML SUSPENSION	muscle spasticity due to multiple sclerosis,muscle spasticity of spinal origin	NEW BRAND	NF		Jul-22
Mar-22	SEGLENTIS 56 MG-44 MG TABLET	postoperative acute pain	NEW BRAND	NF	QL (4 tabs/day), AL (≥ 18 years)	Jul-22
Mar-22	ZIMHI 5 MG/0.5 ML SYRINGE	opioid overdose,opioid-induced respiratory depression	NEW BRAND	NPB	(QL)	Jul-22
Mar-22	RECORLEV 150 MG TABLET	pituitary-dependent Cushing's disease	NEW BRAND	NPS	(SP) (PA) (QL)	Jul-22
Mar-22	SYNOJOYNT 1% SYRINGE	osteoarthritis of the knee	NEW GENERIC	NPS	(SP) (MED) (PA) (QL)	Jul-22
Mar-22	TARPEYO DR 4 MG CAPSULE	proteinuria with primary immunoglobulin A nephropathy	NEW BRAND	NPS	(PA) (QL) (SP)	Jul-22

If you have questions on this update, please contact your Magellan Rx Management account manager. This document is not intended for member distribution.

REVIEW DATE	LABEL NAME	INDICATIONS	CHANGE TYPE	PRECISION	PRECISION UM	EFFECTIVE DATE
Mar-22	VABYSMO 6 MG/0.05 ML VIAL	diabetic macular edema,neovascular age-related macular degeneration	NEW BRAND	NPS	(MED) (PA) (QL) (SP)	Jul-22
Mar-22	VYVGART 400 MG/20 ML VIAL	AChR antibody positive generalized myasthenia gravis	NEW BRAND	NPS	(MED) (PA) (QL) (SP)	Jul-22
Mar-22	INFLIXIMAB 100 MG VIAL	Crohn's disease,ankylosing spondylitis,moderate to severe plaque psoriasis,psoriatic arthritis,rheumatoid arthritis,ulcerative colitis	DRUG CHANGES	NF (PEL)	(MED)(QL)(SP)	Jul-22
Mar-22	ALBUTEROL HFA 90 MCG INHALER	manufacturer: WEST-WARD/HIKMA	DRUG CHANGES	GEN	(QL)	Apr-22
Mar-22	ALBUTEROL HFA 90 MCG INHALER	manufacturer: EXELAN PHARMCEUTICALS	DRUG CHANGES	GEN	(QL)	Jan-22
Mar-22	REGENECARE 2% WOUND GEL		DRUG CHANGES	NPB --> NF	(NFDA)	Jul-22
Mar-22	RINVOQ ER 30 MG TABLET	atopic dermatitis	NEW STRENGTH	PS	(PA) (PS) (SP) (QPD)	Mar-22
Mar-22	ESOMEPRAZOLE MAG DR 20 MG CAP	heartburn, erosive esophagitis, gastric ulcer, GERD, H.pylori	DRUG CHANGES	NF -> GEN	(QL)	Apr-22
Mar-22	ESOMEPRAZOLE MAG DR 40 MG CAP	heartburn, erosive esophagitis, gastric ulcer, GERD, H.pylori	DRUG CHANGES	NF -> GEN	(QL)	Apr-22
Mar-22	ENZADYNE CAPSULE	exocrine pancreatic insufficiency	DRUG CHANGES	NPB-->NF	(NFDA)	Feb-22
Mar-22	SILVASORB GEL		DRUG CHANGES	NPB-->NF	(NFDA)	Mar-22
Mar-22	FENTANYL 2 MCG-ROPIV 0.1%-NS	NFDA opioid anagesic	DRUG CHANGES	NF	(NFDA)(MED)	Mar-22
Mar-22	FENTANYL 2 MCG-ROPIV 0.125%-NS	NFDA opioid anagesic	DRUG CHANGES	NF	(NFDA)(MED)	Mar-22
Mar-22	FENTANYL 2 MCG-ROPIV 0.2%-NS	NFDA opioid anagesic	DRUG CHANGES	NF	(NFDA)(MED)	Mar-22
Mar-22	FLUTICASONE-SALMETEROL 113-14	maintenance therapy for asthma	DRUG CHANGES	GEN-->NF	(QPD)	Jul-22
Mar-22	FLUTICASONE-SALMETEROL 232-14	maintenance therapy for asthma	DRUG CHANGES	GEN-->NF	(QPD)	Jul-22
Mar-22	FLUTICASONE-SALMETEROL 55-14	maintenance therapy for asthma	DRUG CHANGES	GEN-->NF	(QPD)	Jul-22
Mar-22	LOESTRIN 21 1.5-30 TABLET	pregnancy contraception	DRUG CHANGES	NF-->GEN	(GL)	Jul-22
Mar-22	LOESTRIN 21 1-20 TABLET	pregnancy contraception	DRUG CHANGES	NF-->GEN	(GL)	Jul-22
Mar-22	LOESTRIN FE 1.5-30 TABLET	pregnancy contraception	DRUG CHANGES	NF-->GEN	(GL)	Jul-22
Mar-22	LOESTRIN FE 1-20 TABLET	pregnancy contraception	DRUG CHANGES	NF-->GEN	(GL)	Jul-22
Mar-22	FEMCAP 26 MM CERVICAL CAP	Barrier contraceptive	DRUG CHANGES	NPB		Jul-22
Mar-22	FEMCAP 30 MM CERVICAL CAP	Barrier contraceptive	DRUG CHANGES	NPB		Jul-22
Mar-22	NATAZIA 28 TABLET	menorrhagia,pregnancy contraception	DRUG CHANGES	PB	(GL)	Jul-22
Mar-22	NEXTSTELLIS 3-14.2 MG TABLET	pregnancy contraception	DRUG CHANGES	NF		Jul-22
Mar-22	FYAVOLV 0.5 MG-2.5 MCG TABLET	post-menopausal osteoporosis prevention,vasomotor symptoms associated with menopause	DRUG CHANGES	GEN	(GL)(QPD)	Jul-22
Mar-22	FYAVOLV 1 MG-5 MCG TABLET	post-menopausal osteoporosis prevention,vasomotor symptoms associated with menopause	DRUG CHANGES	GEN	(GL)(QPD)	Jul-22
Mar-22	JINTELI 1 MG-5 MCG TABLET	post-menopausal osteoporosis prevention,vasomotor symptoms associated with menopause	DRUG CHANGES	GEN	(GL)(QPD)	Jul-22

If you have questions on this update, please contact your Magellan Rx Management account manager. This document is not intended for member distribution.

REVIEW DATE	LABEL NAME	INDICATIONS	CHANGE TYPE	PRECISION	PRECISION UM	EFFECTIVE DATE
Mar-22	NORETHIN-ETH ESTRAD 1 MG-5 MCG	post-menopausal osteoporosis prevention, vasomotor symptoms associated with menopause	DRUG CHANGES	GEN	(GL)(QPD)	Jul-22
Mar-22	NORETHIND-ETH ESTRAD 0.5-2.5	post-menopausal osteoporosis prevention, vasomotor symptoms associated with menopause	DRUG CHANGES	GEN	(GL)(QPD)	Jul-22

**VALUE ASSESSMENT COMMITTEE HIGHLIGHTS**

REVIEW DATE	LABEL NAME	INDICATIONS	CHANGE TYPE	PRECISION	PRECISION UM	EFFECTIVE DATE
Mar-22	ADAPALENE-BNZYL PEROX 0.3-2.5%	acne vulgaris	NEW GENERIC	GEN	(QPD)	Jul-22
Mar-22	BELBUCA 75 MCG FILM	severe chronic pain requiring long-term opioid treatment	DRUG CHANGES	NPB-->PB	(PA)(QPD)(AL)	May-22
Mar-22	BELBUCA 150 MCG FILM	severe chronic pain requiring long-term opioid treatment	DRUG CHANGES	NPB-->PB	(PA)(QPD)(AL)	May-22
Mar-22	BELBUCA 300 MCG FILM	severe chronic pain requiring long-term opioid treatment	DRUG CHANGES	NPB-->PB	(PA)(QPD)(AL)	May-22
Mar-22	BELBUCA 450 MCG FILM	severe chronic pain requiring long-term opioid treatment	DRUG CHANGES	NPB-->PB	(PA)(QPD)(AL)	May-22
Mar-22	BELBUCA 600 MCG FILM	severe chronic pain requiring long-term opioid treatment	DRUG CHANGES	NPB-->PB	(PA)(QPD)(AL)	May-22
Mar-22	BELBUCA 750 MCG FILM	severe chronic pain requiring long-term opioid treatment	DRUG CHANGES	NPB-->PB	(PA)(QPD)(AL)	May-22
Mar-22	BELBUCA 900 MCG FILM	severe chronic pain requiring long-term opioid treatment	DRUG CHANGES	NPB-->PB	(PA)(QPD)(AL)	May-22
Mar-22	AJOVY 225 MG/1.5 ML AUTOINJECT	migraine prevention	DRUG CHANGES	NF-->PB	(add PA)(QPD)(AL)	Jul-22
Mar-22	AJOVY 225 MG/1.5 ML SYRINGE	migraine prevention	DRUG CHANGES	NF-->PB	(add PA)(QPD)(AL)	Jul-22
Mar-22	EMGALITY 120 MG/ML PEN	migraine prevention	DRUG CHANGES	PB-->NF	(QPD)(AL)	Jul-22
Mar-22	EMGALITY 120 MG/ML SYRINGE	migraine prevention	DRUG CHANGES	PB-->NF	(QPD)(AL)	Jul-22
Mar-22	EMGALITY 100 MG/ML SYR(1 OF 3)	episodic cluster headache, migraine prevention	DRUG CHANGES	PB	(PA)(QPD)(AL)	Jul-22
Mar-22	EMGALITY 300 MG (100 MG X3SYR)	episodic cluster headache, migraine prevention	DRUG CHANGES	PB	(PA)(QPD)(AL)	Jul-22
Mar-22	REXULTI 0.25 MG TABLET	major depressive disorder treatment adjunct, schizophrenia	DRUG CHANGES	NPB	(remove PA)(QPD)(AL)	May-22
Mar-22	REXULTI 0.5 MG TABLET	major depressive disorder treatment adjunct, schizophrenia	DRUG CHANGES	NPB	(remove PA)(QPD)(AL)	May-22
Mar-22	REXULTI 1 MG TABLET	major depressive disorder treatment adjunct, schizophrenia	DRUG CHANGES	NPB	(remove PA)(QPD)(AL)	May-22
Mar-22	REXULTI 2 MG TABLET	major depressive disorder treatment adjunct, schizophrenia	DRUG CHANGES	NPB	(remove PA)(QPD)(AL)	May-22
Mar-22	REXULTI 3 MG TABLET	major depressive disorder treatment adjunct, schizophrenia	DRUG CHANGES	NPB	(remove PA)(QPD)(AL)	May-22
Mar-22	REXULTI 4 MG TABLET	major depressive disorder treatment adjunct, schizophrenia	DRUG CHANGES	NPB	(remove PA)(QPD)(AL)	May-22
Mar-22	VRAYLAR 1.5 MG CAPSULE	depression associated with bipolar disorder, mania associated with bipolar disorder, mixed bipolar I disorder, schizophrenia	DRUG CHANGES	NPB	(remove ST)(QPD)(AL)	May-22
Mar-22	VRAYLAR 3 MG CAPSULE	depression associated with bipolar disorder, mania associated with bipolar disorder, mixed bipolar I disorder, schizophrenia	DRUG CHANGES	NPB	(remove ST)(QPD)(AL)	May-22
Mar-22	VRAYLAR 4.5 MG CAPSULE	depression associated with bipolar disorder, mania associated with bipolar disorder, mixed bipolar I disorder, schizophrenia	DRUG CHANGES	NPB	(remove ST)(QPD)(AL)	May-22
Mar-22	VRAYLAR 6 MG CAPSULE	depression associated with bipolar disorder, mania associated with bipolar disorder, mixed bipolar I disorder, schizophrenia	DRUG CHANGES	NPB	(remove ST)(QPD)(AL)	May-22

If you have questions on this update, please contact your Magellan Rx Management account manager. This document is not intended for member distribution.

REVIEW DATE	LABEL NAME	INDICATIONS	CHANGE TYPE	PRECISION	PRECISION UM	EFFECTIVE DATE
Mar-22	VRAYLAR 1.5 MG-3 MG PACK	depression associated with bipolar disorder,mania associated with bipolar disorder,mixed bipolar I disorder,schizophrenia	DRUG CHANGES	NPB	(remove ST)(QPD)(AL)	May-22
Mar-22	NUVARING VAGINAL RING	pregnancy contraception	DRUG CHANGES	PB-->NF	(GL)	Jul-22
Mar-22	BRIMONIDINE-TIMOLOL 0.2%-0.5%	ocular hypertension,open angle glaucoma	NEW GENERIC	GEN	(QPD)	Jul-22
Mar-22	DEXILANT DR 30 MG CAPSULE	erosive esophagitis,gastroesophageal reflux disease,heartburn,maintenance of healing erosive esophagitis	DRUG CHANGES	PB-->NF	(QPD)	Jul-22
Mar-22	DEXILANT DR 60 MG CAPSULE	erosive esophagitis,gastroesophageal reflux disease,heartburn,maintenance of healing erosive esophagitis	DRUG CHANGES	PB-->NF	(QPD)	Jul-22
Mar-22	DEXLANSOPRAZOLE DR 30 MG CAP	erosive esophagitis,gastroesophageal reflux disease,heartburn,maintenance of healing erosive esophagitis	NEW GENERIC	GEN	(QPD)(add ST)	Jul-22
Mar-22	DEXLANSOPRAZOLE DR 60 MG CAP	erosive esophagitis,gastroesophageal reflux disease,heartburn,maintenance of healing erosive esophagitis	NEW GENERIC	GEN	(QPD)(add ST)	Jul-22
Mar-22	SUMATRIPTAN 6 MG/0.5 ML CART	cluster headache,migraine	DRUG CHANGES	GEN-->NF	(QPD)	Jul-22
Mar-22	BROVANA 15 MCG/2 ML SOLUTION	bronchospasm prevention with COPD	DRUG CHANGES	NPB-->NF	(QPD)	Jul-22
Mar-22	XIIDRA 5% EYE DROPS <sup>®</sup>	NDC: 54092060606	DRUG CHANGES	PB-->NF	(QPD)(AL)	Jul-22
Mar-22	MESALAMINE 800 MG DR TABLET <sup>®</sup>	treatment of moderately active ulcerative colitis in adults.	DRUG CHANGES	NF-->NPB	(PA)	Jul-22

KEY:	
ABBREVIATION	DEFINITION
GEN	Generic

If you have questions on this update, please contact your Magellan Rx Management account manager. This document is not intended for member distribution.

REVIEW DATE	LABEL NAME	INDICATIONS	CHANGE TYPE	PRECISION	PRECISION UM	EFFECTIVE DATE
	<b>GEN (SP)</b>	Generic (Specialty)				
	<b>PB</b>	Preferred Brand				
	<b>NPB</b>	Non-Preferred Brand				
	<b>PS</b>	Preferred Specialty				
	<b>NPS/SP</b>	Non-Preferred Specialty/Specialty				
	<b>NF</b>	Non-Formulary				
	<b>QL/QPD</b>	Quantity Limit				
	<b>GL</b>	Gender Limit				
	<b>ST</b>	Step Therapy				
	<b>PA</b>	Prior Authorization				
	<b>MED</b>	Medical Flag				
	<b>BSP</b>	Benefit Shift Program				
	<b>NFDA</b>	Non-FDA Approved				
	<b>B4G</b>	Brand for generic				
	<b>SDS</b>	Extended Specialty Day Supply				
	<b>HCR</b>	Healthcare Reform				
	*	Manage consistent with other drugs in class, unless otherwise specified				
	<sup>a</sup>	Clinically similar products				

If you have questions on this update, please contact your Magellan Rx Management account manager. This document is not intended for member distribution.